pp-107 Tablets
Dossier type
EU CTD
Dossier status
Under development
Country of origin
European Union
Comments
Indication: Progressive supranuclear palsy (PSP), a rare, rapidly progressing tau‑associated neurodegenerative disorder in adults
Clinical stage: Phase 2 clinical development with topline recruitment completed
Modality: Small molecule
Mechanism / Target: Selective O‑GlcNAcase (OGA) enzyme inhibition to increase tau O‑GlcNAcylation and potentially reduce pathological tau aggregation
Route / form: Oral administration (tablet)
Differentiation: Brain‑penetrant OGA inhibitor targeting tau pathology with potential disease‑modifying effects in PSP where no approved therapies exist
Manufacturer #12186
The activity of the company is based on the development of highly competitive processes for the manufacture of active ingredients with high added value that meet the strictest quality specifications. They manufacture under strict compliance with the environmental and occupational safety regulations in force in Europe. They focus on the pharmaceutical, hospital, diagnostic, fine chemical, and food fields. Its products are marketed in more than 70 countries.
Manufacturer usually replies in 2 days